Press Release

Regenerative Medicine Market 2018-2026: Key Player, Demand, Growth, Opportunities and Forecast

Regenerative Medicine Market: 2019 Market Share, Competitive Landscape, Key Players, Worldwide Opportunities

The Global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published by Fortune Business Insights, titled “Regenerative Medicine: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 23,841.5 Mn in 2018.

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Key players leading the Global Regenerative Medicine Market include

  • Integra LifeSciences Corporation,
  • CELGENE CORPORATION,
  • Medtronic,
  • American CryoStem Corporation,
  • Tissue Regenix,
  • Avita Medical,
  • Osiris Therapeutics, Inc.,
  • Wright Medical Group N.V.,
  • Smith & Nephew,
  • Integra LifeSciences Corporation.

Fortune Business Insights states that The Regenerative Medicine Market will reach US$ 151,949.5 Mn by the end of 2026, thereby exhibiting a CAGR of 26.1%.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Integra LifeSciences’ Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer ‘Thin’. The product was aimed at repairing dermal defects in a one-step procedure. The medicine will also aid in reducing hospital stays. Fortune Business Insights has identified Integra’s latest product offering as a major market growth driver. The report includes product launches, similar to Integra’s latest medicine and gauges the impact of these products on the global regenerative medicine Industry in the coming years.

Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines. In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine ‘Luxturna’. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases. Fortune Business Insights states that the approval for Luxturna will contribute to the growth of the global regenerative medicine market in the forthcoming years.

Order Complete [email protected] https://www.fortunebusinessinsights.com/checkout-page/100970

Segmentation

By Product

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Platelet Rich Plasma

By Application

  • Orthopedics
  • Wound Care
  • Oncology
  • Others

By Distribution Channel

  • Hospitals
  • Clinics

More Trending Topics From Fortune Business [email protected] 

ePharmacy Market to Reach US$ 177,794.9 Mn by 2026; Expansion of Online Retailing to Boost Growth, says Fortune Business Insights

Glaucoma Therapeutics Market to Reach US$ 10,091.0 Mn by 2026, Increasing Prevalence of Glaucoma to Provide Impetus, says Fortune Business Insights

Tags

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close